SEC Form 4 · accession 0001470831-26-000801
Braveheart Bio, Inc. · BRVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Viehbacher
Director
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 4:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002131524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2026 | P | 83,333 | $18.00 | A | 609,519 | D | |
| Common StockF1 | holding | — | — | — | 150,338 | I | By CAV FAMILY LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $18.00 | Aug 5, 2026 | A | 30,000 | A | — | Aug 4, 2036 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
- F2The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.